Managing diabetes for years is often a major challenge for patients, where every daily activity must be carefully calculated to maintain stable blood sugar levels. For decades, people with type 1 and type 2 diabetes have faced constant emotional and physical burdens due to limited information and invasive monitoring methods.
Now, this paradigm is shifting with the advent of Continuous Glucose Monitoring (CGM) technology. This innovation allows patients to monitor glucose levels in real-time without the need for repeated finger pricks. Feedback from patients shows that this technology not only provides easy access to data, but also significantly reduces anxiety levels, especially in preventing the risk of dangerous hypoglycemia.
As a demonstration of its commitment to digital health transformation, Abbott has officially launched the FreeStyle Libre 2 Plus sensor in the Vietnamese market. This next-generation device meets the FDA's iCGM standards, offering high accuracy and customizable early warning systems. The introduction of this technology aligns with the latest recommendations from the American Diabetes Association (ADA), which encourage the early use of CGM.
Douglas Kuo, Abbott's Vice President for Vietnam, Australia, and New Zealand, emphasized that this solution is designed to enable patients to make appropriate medical decisions based on accurate data. This step is also aligned with the local government's policy regarding the acceleration of digital transformation in the healthcare sector, which aims to improve public quality of life through access to more advanced services.
In addition to hardware innovation, Abbott continues to promote a holistic health approach that includes continuous education and science-based nutrition. This integration of advanced technology and lifestyle support is expected to empower people with diabetes in Vietnam to carry out their daily activities with greater peace of mind and productivity.
